Cingulate (CING) CEO awarded options tied to 2027 FDA decision on CTx-1301
Rhea-AI Filing Summary
Cingulate Inc. reported that Chief Executive Officer and director Shane J. Schaffer received two grants of stock options on July 16, 2026. One grant covers 197,650 options and a second covers 97,350 options, each exercisable for common stock at an exercise price of $4.43 per share and expiring on July 16, 2036. The options vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For the 97,350-option grant, even vested options only become exercisable if Cingulate’s NDA for CTx-1301 is approved by the FDA during 2027; if that NDA is not approved during 2027, this option grant, including any vested portion, terminates.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Schaffer Shane J.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to Buy) F1 | 197,650 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to Buy) F1, F2, F3 | 97,350 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to Buy) — 295,000 shares (Direct)
Footnotes (3)
- F1. The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
- F2. Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
- F3. If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.
Key Figures
Option grant 1: 197,650 options
Option grant 2: 97,350 options
Exercise price: $4.43 per share
+4 more
7 metrics
Option grant 1
197,650 options
Stock Option (right to Buy) granted to CEO on July 16, 2026
Option grant 2
97,350 options
Additional Stock Option (right to Buy) granted to CEO on July 16, 2026
Exercise price
$4.43 per share
Conversion or exercise price for both option grants
Expiration date
July 16, 2036
Expiration for both stock option grants
Initial vesting
25% on March 31, 2027
First tranche vesting date for both grants
Remaining vesting period
36 months
Remainder vests in substantially equal monthly installments
NDA approval window
Year 2027
CTx-1301 NDA must be approved by FDA in 2027 for one grant to be exercisable
Key Terms
Stock Option (right to Buy, NDA, CTx-1301, FDA, +1 more
5 terms
Stock Option (right to Buy financial
"security_title: "Stock Option (right to Buy)" for both grants"
NDA medical
"If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
CTx-1301 medical
"Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved"
FDA regulatory
"approved by the FDA during 2027"
The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.
vested option financial
"Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock options did Cingulate (CING) CEO Shane Schaffer receive on July 16, 2026?
Cingulate’s CEO Shane J. Schaffer received two stock option grants: one for 197,650 options and another for 97,350 options, each over common stock at a $4.43 exercise price, expiring July 16, 2036, as part of his equity compensation.
What is the exercise price and expiration date of the new CING options granted to Shane Schaffer?
Both new option grants carry an exercise price of $4.43 per share and expire on July 16, 2036. Each option is a right to buy Cingulate common stock at that fixed price if and when the options vest and become exercisable.
How do the vesting terms work for Shane Schaffer’s new Cingulate (CING) stock options?
The options vest 25% on March 31, 2027, with the remaining shares vesting in substantially equal monthly installments over the next 36 months. Vesting is time-based, subject to additional exercisability conditions on one of the grants tied to regulatory approval.
What regulatory milestone affects exercisability of part of Shane Schaffer’s Cingulate (CING) options?
For the 97,350-option grant, vested options become exercisable only if Cingulate’s NDA for CTx-1301 is approved by the FDA during 2027. If that NDA is not approved during 2027, this entire option, including any vested portion, terminates.
Were Shane Schaffer’s July 2026 Cingulate (CING) option grants made under a Rule 10b5-1 trading plan?
The filing indicates the Rule 10b5-1 checkbox is not marked, and the transactions are reported as grant/award acquisitions of stock options, rather than trades executed under a pre-arranged 10b5-1 trading plan in the open market.